Clinical Trial · NCT04255628

The Brain Metabolic Change in Chronic Cancer Pain Patient: FDG PET Image Study

Overview

Cancer pain deteriorated in quality of life and related with numerous psychosocial problems. Over the one third of cancer patient suffered from moderate to severe cancer pain, even under adequate pain management. The 18F-fluoro-2-deoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) images can provide quantitative results in clinical oncology. As a functional neuroimaging, the PET evidently provided anatomical activated regions, size, and spatial extent information. In this study, we use FDG-PET to investigate changes concerning the glucose metabolism in the brain with or without cancer pain. Therefore, we may provide useful information to treatment target in cancer pain patients.

Sponsor

National Taiwan University Hospital

Phase

N/A

Contacts

Wen-ying Lin

ying434@gmail.com

+886972652006

ClinicalTrials.gov

NCT04255628

Drug / Compound

Isotope(s):
Target(s):